Tumors that metastasize are considered "malignant" by definition. However, benign giant-cell tumor of bone is an exception because of the potential for histologically benign pulmonary metastases, a fact seldom emphasized in the radiologic literature. We therefore report our experience with 13 cases of pulmonary metastasis among 475 patients (prevalence, 3%) in whom benign giant-cell tumor of bone was diagnosed before 1990 at our institution. Five (38%) of the 13 primary bone tumors were located in the distal radius. Local recurrence at the site of the primary bone tumor tumor occurred in seven patients (54%) before pulmonary metastases developed. The mean interval from the diagnosis of the primary bone tumor to the onset of pulmonary metastasis was 3.8 years, with a maximum of 10.7 years. Fifty-four percent of the patients (7/13) had pulmonary metastases 3 years after diagnosis of the primary bone lesion, and 92% (12/13) had pulmonary metastases 7.5 years after diagnosis. Overall mortality rate directly due to giant-cell tumor and its metastases was 23%. On chest radiographs and CT scans, pulmonary metastases appeared as rounded, nodular opacities of homogeneous density, ranging from 0.5 cm to 8.0 cm in diameter. Peripheral regions of the lungs were involved in 85% of the cases and basilar regions in 62%. Our study shows that benign giant-cell tumor of bone can produce pulmonary metastases, that metastases most often occurred with recurrent local disease and distal radial lesions, that the prognosis was relatively favorable, and that such metastases had no distinguishing radiologic features.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2214/ajr.158.2.1729794 | DOI Listing |
Chirurgie (Heidelb)
January 2025
Klinik und Poliklinik für Chirurgie, Sektion Thoraxchirurgie, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland.
Video-assisted thoracic surgery (VATS) is a safe and effective surgical procedure. Completely minimally invasive operations must be distinguished from hybrid procedures. The VATS can be used for diagnostic and treatment purposes for all oncological and non-oncological diseases of the thoracic organs.
View Article and Find Full Text PDFJ Thorac Dis
December 2024
Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Background: Spontaneous pneumothorax (SP) has been reported to be associated with osteosarcoma lung metastases, but the computed tomography (CT) characteristics of lung metastases in patients with pneumothorax have not been comprehensively described. The study aimed to describe the CT characteristics of lung metastases in patients with osteosarcoma and to identify factors associated with SP.
Methods: This study comprised 123 patients diagnosed with osteosarcoma lung metastasis at our hospital between January 2016 and December 2021.
Transl Lung Cancer Res
December 2024
Department of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Background: Health-related quality of life (HRQoL) is critical for patients with lung cancer due to poor prognosis. We presented patient-reported outcomes in patients with non-small cell lung cancer (NSCLC) brain metastases (BM) who received whole-brain radiotherapy (WBRT) in combination with erlotinib or WBRT alone in the phase 3 ENTER study.
Methods: The patients' HRQoL was assessed by using the European Organization for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire (EORTC QLQ-C30).
Transl Lung Cancer Res
December 2024
Department of Thoracic Surgery, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Background And Objective: Pulmonary carcinoids (PCs) represent a rare subset of neuroendocrine tumors (NETs) within the respiratory tract that exhibit unique characteristics and clinical behaviors. These tumors are currently staged according to the tumor-nodules-metastases (TNM) classification of non-small cell lung cancer (NSCLC), which brings their reliability into question. The aim of this study was to assess reliability of the current TNM staging of PCs and explore other relevant prognostic factors of patient outcomes.
View Article and Find Full Text PDFTransl Lung Cancer Res
December 2024
School of Medicine, Southeast University, Nanjing, China.
Background: Resistance to chemoimmunotherapy in patients with advanced non-small cell lung cancer (NSCLC) necessitates effective prognostic biomarkers. Although F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) has shown potential for efficacy assessment, it has been mainly evaluated in immuno-monotherapy setting, lacking elaborations in the scenarios of immunotherapy combined with chemotherapy. To tackle this dilemma, we aimed to build a non-invasive PET/CT-based model for stratifying tumor heterogeneity and predicting survival in advanced NSCLC patients undergoing chemoimmunotherapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!